Bradykinin B2 receptor - (CHAPTER-1)

July 22, 2026: Pharvaris (NASDAQ: PHVS) announced publication of a review article in Clinical Reviews in Allergy & Immunology titled “Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes.” The article summarizes evidence on bradykinin biology and the bradykinin B2 receptor (B2R), supporting B2R antagonism as a clinically validated therapeutic strategy for bradykinin-mediated angioedema, including hereditary angioedema (HAE, including HAE with normal C1 inhibitor) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), and discusses potential relevance to broader immunological/inflammatory disorders.

The release notes Pharvaris is developing oral B2R antagonists, including deucrictibant immediate-release capsules and extended-release tablets in late-stage global clinical trials, and references ongoing/future studies (including CHAPTER-3 and CREAATE). It also mentions regulatory risk factors including the outcome of an NDA for on-demand treatment of acute HAE attacks, but provides no filing date, acceptance, PDUFA/action date, or decision timing.